From Inception, Tempest Plans To Kick Up IO Storm

Emerging Company Profile: Spinning out of Versant Ventures’ Inception Sciences, San-Francisco-based development-stage biotech Tempest Therapeutics Inc. completes $70m Series B round to advance small molecules that modulate anti-tumor immunity pathways.